6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02424708 (ClinicalTrials.gov)	April 2015	15/4/2015	Phase IIb Study of Intranasal Glutathione in Parkinson's Disease	Phase IIb Study of Intranasal Glutathione in Parkinson's Disease	Parkinson's Disease	Drug: Reduced Glutathione 100mg;Drug: Reduced Glutathione 200mg;Drug: Placebo	Bastyr University	Michael J. Fox Foundation for Parkinson's Research	Completed	21 Years	N/A	Both	45	Phase 2	United States
2	NCT02324426 (ClinicalTrials.gov)	December 2014	4/12/2014	CNS Uptake of Intranasal Glutathione	Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease	Parkinson's Disease	Drug: Reduced Glutathione	University of Washington	Michael J. Fox Foundation for Parkinson's Research	Completed	18 Years	N/A	Both	15	Phase 1	United States
3	NCT01398748 (ClinicalTrials.gov)	July 2012	19/7/2011	Intranasal Glutathione in Parkinson's Disease	A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease	Parkinson's Disease (PD)	Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal Delivery	Bastyr University	National Center for Complementary and Integrative Health (NCCIH)	Completed	21 Years	100 Years	All	34	Phase 1	United States